Wednesday, October 14, 2026

Infrastructure Investment

4 articles

Nevada Data Centers on Track to Consume 35% of State Power by 2030, Reshaping Energy Investment

Nevada Data Centers on Track to Consume 35% of State Power by 2030, Reshaping Energy Investment

A 2026 study projects Nevada data centers will account for 35% of the state's electricity consumption by 2030, signaling that AI infrastructure power demand has crossed into a systemic grid-level constraint. The shift is accelerating capital flows into utilities, power generation, and energy infrastructure M&A. Investors are repositioning toward AI-adjacent REITs and natural gas and nuclear assets as hyperscalers face rising electricity costs.

LM Salvado•
Nigeria's NSIA Deploys Sovereign Capital Into AI Infrastructure as Kasi LOS1 Goes Live

Nigeria's NSIA Deploys Sovereign Capital Into AI Infrastructure as Kasi LOS1 Goes Live

Nigeria's sovereign wealth fund, NSIA, has committed capital to AI infrastructure in a funding event timed with the commissioning of the Kasi LOS1 facility. Policy, regulation, subsea connectivity, and state capital are converging simultaneously. The move positions West Africa for a wave of local AI compute access within 6 to 18 months.

LM Salvado•
Network Automation Platform Netris Posts 622% Growth as AI Infrastructure Deployment Reaches 20+ Cloud Centers

Network Automation Platform Netris Posts 622% Growth as AI Infrastructure Deployment Reaches 20+ Cloud Centers

Netris captured 622% year-over-year revenue growth deploying network automation across 20+ AI cloud facilities, solving manual configuration error rates that reach 20%. The platform's expansion coincides with VCI Global operationalizing Southeast Asia's first NVIDIA-powered GPU computing center in Singapore, targeting Asia-Pacific's accelerating AI infrastructure market. Industry analysts project trillions in required AI infrastructure investment, with only hundreds of billions deployed to date.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com